Arrowhead Research | ARWR - Ordinary Share Capital


Arrowhead Research reported $135.7M in Ordinary Share Capital for its fiscal quarter ending in September of 2025.





Ordinary Share Capital Change Date
Agios Pharmaceuticals USD 58.28M 241K Sep/2025
Alnylam Pharmaceuticals USD 131.79M 130.49M Sep/2025
Arrowhead Research USD 135.7M 2.44M Sep/2025
Incyte USD 196.13M 2.01M Sep/2025
Ionis Pharmaceuticals USD 161.14M 160.98M Sep/2025
Ligand Pharmaceuticals USD 20K 0 Mar/2025
Merck USD 2.5B 715.14M Jun/2025
Moderna USD 391M 2M Sep/2025
Novartis USD 1.94B 23.4M Jun/2025
Sarepta Therapeutics USD 104.77M 7.06M Sep/2025
TG Therapeutics USD 155.21M 2.81M Sep/2025
Ultragenyx Pharmaceutical USD 96.44M 88K Sep/2025
Vertex Pharmaceuticals USD 254M 2.29M Sep/2025
Xencor USD 71.34M 46K Sep/2025